Arkin Holdings is dedicated to empowering companies that create breakthrough pharma, biotech and medical device technologies.
Our synergistic healthcare investments are dedicated to creating innovations that benefit humanity and enhance medical care. The Arkin Holdings family office and investment management team offer extensive experience and a proven track record of successful healthcare investments.
Founder and Chairman
Mr. Arkin is one of Israel’s most successful life sciences and pharmaceutical entrepreneurs.
He headed Agis, growing it into a leading dermatological company in the U.S., until its acquisition by Perrigo in 2005 for $818 million. Mr. Arkin has extensive experience in the development and commercialization of pharmaceutical drug products, having held leadership roles in several companies with significant ties to innovative and generic drug companies. He holds a degree in psychology and philosophy from the Tel Aviv University.
Mr. Nir Arkin took the lead in managing the family office in 2014, after a period of specializing in the various areas of the group’s activities. He serves on the board of directors of Sphera Global Healthcare, as well as being a member of both Accelmed`s and Sphera Global Healthcare investment committees. Mr. Nir Arkin holds a LLB degree and a BA from Interdisciplinary Center in Herzliya and is also a member of the Israeli Bar.
After completing his internship at Sphera investment fund, Mr. Itai Arkin joined Arkin Holdings in March 2014, as a research analyst for market research in the field of dermatology and investments. He serves on the board of directors of Exalenz Bioscience, and is also a member of both Accelmed and Sphera Global Healthcare investment committees. Mr. Itai Arkin graduated with honors a BA degree in Business Administration from IDC Herzliya.
Head of Pharma
Dr. Pini Orbach joined Arkin Holdings in 2010 as Head of its Pharma Division. Dr. Orbach is a member of the board in several of its pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, from which he shares his extensive hands-on drug development and business experience. He originally gained his foundation in US based companies such as, Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ, EPIX), as well as Israeli-based companies such as, cCAM BioTherapeutics - a cancer immunotherapy company, which was sold to Merck in 2015 for $605M.
He holds a Ph.D. from the Department of Physiology and Functional Genomics, University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center, Harvard Medical School - Massachusetts General Hospital.
Mrs. Lerman, who joined Arkin Holdings as CFO in 2015, has been a finance executive and consultant for more than 15 years. She serves as a board member of several companies, including Sphera Global Healthcare, Exalenz Bioscience, and Medical Compression Systems. Prior to joining Arkin Holdings, she was CFO of high-tech companies including, Discretix, Storwize and SunGard Business Integration. She holds an MBA, with a major in Finance from Tel Aviv University, a B.A. in Economics and Accounting .
Biotech Investment Manager
Dr. Alon Lazarus joined Arkin Holdings' Pharma Division in 2013. He is a member of the Board of several of its pharmaceutical companies, including Quiet Therapeutics, Keros Therapeutics and Lutris Pharma. Prior to joining Arkin, Dr. Lazarus worked for the Healthcare Business Development Department of Yissum - the Research & Development arm of the Hebrew University of Jerusalem. Dr. Lazarus holds a Ph.D in Molecular Biology and an MBA - both from the Hebrew University of Jerusalem in Israel.
HEAD OF REAL ESTATE INVESTMENTS
Mr. Bar brings over 20 years of experience in financial consulting and real estate investments including direct and corporate investments, listed vehicles, real estate debt structures etc. Prior to joining Arkin Holdings, Mr. Bar served as the Head of International Real Estate Investments at Migdal Insurance, after serving as Real Estate Investments Manager and as Senior Research Analyst for the company. Prior to that, Mr. Bar worked as Senior Manager for Deloitte, as well as for other financial consulting firms, in various positions.
Mr. Bar holds an MBA from Tel Aviv University, majoring in finance, and a B.A. in Economics and Accounting from Tel Aviv University (both cum laude). Mr. Bar is a certified public accountant.